Leerink Partners Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an Outperform rating on WAVE Life Sciences and raised its price target from $20 to $22.
October 16, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has maintained an Outperform rating on WAVE Life Sciences and increased the price target from $20 to $22, indicating positive expectations for the stock.
The increase in price target from $20 to $22 by Leerink Partners suggests a positive outlook for WAVE Life Sciences. The Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100